(NASDAQ: APGE) Apogee Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Apogee Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast APGE's revenue for 2028 to be $8,151,936,208, with the lowest APGE revenue forecast at $8,151,936,208, and the highest APGE revenue forecast at $8,151,936,208. On average, 2 Wall Street analysts forecast APGE's revenue for 2029 to be $14,461,951,355, with the lowest APGE revenue forecast at $6,074,680,055, and the highest APGE revenue forecast at $22,849,222,656.
In 2030, APGE is forecast to generate $59,830,749,028 in revenue, with the lowest revenue forecast at $39,093,591,888 and the highest revenue forecast at $80,567,906,168.